HypeCheck

Updated · AI-assisted evidence analysis

Flexadin® Advanced with UC•II® Review 2026: What Does the Evidence Show?

Dog evidence for UC-II is real but thin; 'proven better' overreaches — Overhyped

See full analysis ↓ Methodology →
Share: Post Share

Claims vs Evidence

3 claims assessed. Support depends on the study results, formulation, and population. Matching an ingredient or dose alone does not establish a benefit.

"Helps maintain joint function, mobility and flexibility" Partial

Dog studies show improved pain and mobility scores with UC-II. The 2012 placebo trial used 10 mg active UC-II, the amount the label lists as active; the 2007 trial states 10 mg UC-II without calling it active. The two Flexadin Advanced studies had no placebo group, the placebo trials were very small, and a 2022 meta-analysis (dogs and cats) called collagen efficacy weak. Flexibility was not measured as such in the retrieved text.

Source: Evaluation of the Effects of Undenatured Type II Collagen (UC-II) as Compared to Robenacoxib on the Mobility Impairment Induced by Osteoarthritis in Dogs. →

UC-II (Flexadin Advanced) compared with robenacoxib in dogs with osteoarthritis

Randomized, controlled, prospective clinical study; the examining clinician was blinded to treatment; no placebo group; robenacoxib was the comparator · formulation match unverified

Owner-rated mobility (LOAD) scores fell 32.7% with UC-II and 31.5% with robenacoxib. Both changes were statistically significant, so the two groups improved by a similar amount.

Limitations: No placebo or untreated group, so improvement can't be attributed to UC-II alone. Only 30 days. Owner-reported primary outcome. Retrieved text was truncated before the non-inferiority results; tablet versus chew form differs.

Species
dog
Participants / condition
60 client-owned dogs with radiographic osteoarthritis; 30 per group
Formulation
Flexadin Advanced, described as 1 tablet (40 mg) daily; the current product is a chew
Studied amount, not dosing advice
1 tablet (40 mg) daily; active UC-II content not stated in the retrieved text; not per kg
Duration
30 days
Funding / conflicts
Authors report no external funding and no conflict of interest. The same lead author later ran a Vetoquinol-funded trial (pmid39475935).
Study source ↓
Long-term Flexadin Advanced in dogs with degenerative joint disease

Multicentre prospective exploratory study; single arm, no control group · formulation match unverified

Veterinarian and owner scores for pain, general condition, appetite, mobility and lameness were significantly lower at every month than at inclusion (p<0.0001). Compliance was good at 3 months but significantly lower at 6 months.

Limitations: Abstract only. No control group, so natural fluctuation and expectation effects can't be excluded. Effect sizes not available. Blinding not reported.

Species
dog
Participants / condition
110 client-owned dogs with clinically diagnosed degenerative joint disease (mild to moderate per authors)
Formulation
FLEXADIN Advanced containing UC-II; form not stated in abstract
Studied amount, not dosing advice
Not reported in abstract
Duration
6 months
Funding / conflicts
Not reported in the retrieved abstract; funder and conflicts unavailable.
Study source ↓
UC-II compared with cimicoxib and their combination in dogs with osteoarthritis

Randomized controlled veterinary trial with an untreated control group · ingredient

Owner-rated LOAD score fell 31.4% with UC-II and was lower than in the untreated group (P=0.001). MOBILITY score was also lower than in untreated dogs (P=0.01).

Limitations: Abstract only. Untreated control, not placebo; blinding not described in the abstract. Short duration. Group sizes not reported.

Species
dog
Participants / condition
76 client-owned dogs that completed the study, with osteoarthritis
Formulation
UC-II, 1 tablet per day; product and tablet content not stated in abstract
Studied amount, not dosing advice
1 tablet per day; active UC-II amount not reported in abstract
Duration
30 days
Funding / conflicts
Not reported in the retrieved abstract; unavailable.
Study source ↓
UC-II plus Boswellia chew versus placebo in dogs with mild/moderate mobility disorders

Randomized, double-blind, placebo-controlled cross-over trial · different formulation

Owner-rated mobility impairment improved with the supplement, already at 4 weeks. Without it, OA crises were more frequent and pain threshold on the most affected joint fell.

Limitations: Contains Boswellia and other ingredients, so effects can't be credited to UC-II or to the plain Flexadin Advanced chew. Only 17 dogs. Single centre.

Species
dog
Participants / condition
17 dogs with mild/moderate OA randomized, from 60 screened
Formulation
Flexadin Advanced Boswellia chew (3 g): UC-II 40 mg, Boswellia serrata 190 mg, omega-3 84 mg, EPA 9.3 mg, vitamin E
Studied amount, not dosing advice
1 chew daily, containing 40 mg UC-II product
Duration
8 weeks per period, 4-week washout, 20 weeks in total
Funding / conflicts
Funded by Vetoquinol SA. One author is Vetoquinol's Global Medical Manager and took part in study design and manuscript review.
Study source ↓
UC-II, glucosamine and chondroitin in arthritic dogs: force plate pain evaluation

Randomized controlled trial with placebo · ingredient

Observed pain fell significantly in UC-II, glucosamine-chondroitin and combination groups. Force-plate peak vertical force and impulse area rose significantly only in the UC-II group. No changes in physical, liver or kidney measures.

Limitations: Abstract only. Very small groups. Effect sizes, blinding details and funding not available.

Species
dog
Participants / condition
Client-owned dogs with moderate arthritis; 7–10 per group in 4 groups
Formulation
UC-II alone, glucosamine plus chondroitin, or combination; brand and product details not stated in abstract
Studied amount, not dosing advice
10 mg active UC-II daily, flat amount; glucosamine 2000 mg and chondroitin 1600 mg
Duration
150 days
Funding / conflicts
Not reported in retrieved abstract; unavailable.
Study source ↓
"Can ease joint stiffness" Partial

Dog trials of UC-II show less pain and lameness, which are related to stiffness, but stiffness was not reported as its own outcome in the retrieved text. The evidence is small, short or uncontrolled.

Source: Therapeutic Efficacy and Safety of Undenatured Type II Collagen Singly or in Combination with Glucosamine and Chondroitin in Arthritic Dogs. →

UC-II alone or with glucosamine and chondroitin in arthritic dogs

Placebo-controlled study, four groups · ingredient

UC-II alone reduced overall pain by 62%, pain on limb manipulation by 91% and exercise-associated lameness by 78% at 120 days. Pain relapsed after withdrawal. No adverse effects or lab changes were reported.

Limitations: Abstract only. Five dogs per group. Blinding and statistics beyond significance not available. Stiffness was not a named outcome.

Species
dog
Participants / condition
20 dogs with arthritis, 5 per group
Formulation
UC-II 10 mg; glucosamine 2000 mg plus chondroitin 1600 mg; or both; no brand named in abstract
Studied amount, not dosing advice
10 mg UC-II daily, flat amount; the abstract does not state this as active collagen
Duration
120 days, then 30-day withdrawal
Funding / conflicts
Not reported in retrieved abstract; unavailable.
Study source ↓
Long-term Flexadin Advanced in dogs with degenerative joint disease

Multicentre prospective exploratory study; single arm, no control group · formulation match unverified

Pain, mobility and lameness scores were significantly lower at all monthly visits than at inclusion. Stiffness not named in abstract.

Limitations: Abstract only. No control group. Effect sizes unavailable. Compliance fell by 6 months.

Species
dog
Participants / condition
110 client-owned dogs with degenerative joint disease
Formulation
FLEXADIN Advanced containing UC-II; form not stated in abstract
Studied amount, not dosing advice
Not reported in abstract
Duration
6 months
Funding / conflicts
Not reported in retrieved abstract; unavailable.
Study source ↓
"Helps enhance a pet's normal repair of cartilage and joints; promotes normal cartilage health" No evidence found

No dog study retrieved measured cartilage repair or structure. Trials looked at pain, lameness, mobility and, in two small studies, synovial-fluid chemistry. A 2022 review said terms like disease-modifying do not yet apply to pet OA approaches, and a scoping review said more studies are needed on whether UC-II prevents OA. This is absence in the search, not a finding of no effect.

Source: Flexadin® Advanced with UC•II®: manufacturer product page →

Signals

  • The label says UC-II is clinically proven more effective than glucosamine and chondroitin, citing a 2007 study of 20 dogs with five per group.
  • The claim that it works differently from hydrolyzed collagen, glucosamine, chondroitin or CBD was not tested in a head-to-head dog study in the reviewed material.
  • 'Innovative,' 'breakthrough' and 'unique formula' are marketing words with no supporting data in the reviewed material.
  • 'Dogs and cats love the taste' has no palatability data in the reviewed material; the 110-dog study reported lower compliance at 6 months.
  • The label prints 40 mg UC-II collagen and 10 mg active type II collagen per chew, with one chew daily.
  • Vetoquinol USA is listed in the NASC member directory with the Quality Seal, a company-level audit that does not test this product (nasc).
  • Flexadin Advanced was named in two published dog studies (pmid31487772, pmid35342740).

Dose vs studies

Label amounts at the label's daily directions, per kg of body weight, compared with what dogs studies used. This compares the label with research. It is not dosing advice.

UC-II brand collagen (chicken cartilage) Not comparable

Label: 40 mg per chew

Studied: 10 mg/day active UC-II

The label gives no dosing table by weight.

Evidence checks

Species and formulation relevance

All graded evidence is from dogs. Two studies name Flexadin Advanced, but one calls it a tablet and the other doesn't state the form, so chew equivalence is unverified. Other trials tested UC-II alone or a Boswellia version. No placebo-controlled trial of this exact product was found in this search.

Label transparency

The label lists 40 mg UC-II brand collagen per chew, yielding 10 mg active type II collagen. That matches the 10 mg active UC-II daily amount in the 2012 dog placebo trial. The 2007 abstract states 10 mg UC-II without saying it was active, so that match isn't confirmed. Per-kg comparison isn't possible: the label gives no weight-based dosing and the studies give no body weights. The page doesn't show a certificate of analysis or lot testing.

Independent quality testing

Vetoquinol USA appears in the NASC member list with the Quality Seal, checked 2026-11-03. This is a company-level audit by an industry association, not a regulator, and it does not test or approve this product. No product-specific independent test result appeared in the reviewed material.

Funding and independence of the research

The 2019 Flexadin Advanced trial reported no external funding, though the same lead author's 2024 trial was funded by Vetoquinol. Funding for the 110-dog study and the 2007 and 2012 trials was not available in the retrieved text. The 2022 meta-analysis authors disclosed prior work for Vetoquinol among other companies, so independence can't be assumed.

Sources (10)

  1. 1. Flexadin® Advanced with UC•II®: manufacturer product page →

    Manufacturer · Accessed 2026-11-04

  2. 2. NASC member list, checked 2026-11-03 →

    Quality standard · Accessed 2026-11-03

  3. 3. Therapeutic Efficacy and Safety of Undenatured Type II Collagen Singly or in Combination with Glucosamine and Chondroitin in Arthritic Dogs. →

    Study · Accessed 2026-11-04

  4. 4. Comparative therapeutic efficacy and safety of type-II collagen (UC-II), glucosamine and chondroitin in arthritic dogs: pain evaluation by ground force plate. →

    Study · Accessed 2026-11-04

  5. 5. Evaluation of the Effects of Undenatured Type II Collagen (UC-II) as Compared to Robenacoxib on the Mobility Impairment Induced by Osteoarthritis in Dogs. →

    Study · Accessed 2026-11-04

  6. 6. Evaluation of clinical efficacy of undenatured type II collagen supplementation compared to cimicoxib and their association in dogs affected by natural occurring osteoarthritis. →

    Study · Accessed 2026-11-04

  7. 7. A 2022 Systematic Review and Meta-Analysis of Enriched Therapeutic Diets and Nutraceuticals in Canine and Feline Osteoarthritis. →

    Research review · Accessed 2026-11-04

  8. 8. Management of Osteoarthritis and Joint Support Using Feed Supplements: A Scoping Review of Undenatured Type II Collagen and <i>Boswellia serrata</i>. →

    Research review · Accessed 2026-11-04

  9. 9. Effects of a feed supplement, containing undenatured type II collagen (UC II®) and Boswellia Serrata, in the management of mild/moderate mobility disorders in dogs: A randomized, double-blind, placebo controlled, cross-over study. →

    Study · Accessed 2026-11-04

  10. 10. Long-term supplementation with an undenatured type-II collagen (UC-II<sup>®</sup>) formulation in dogs with degenerative joint disease: Exploratory study. →

    Study · Accessed 2026-11-03

How this report was produced

AI-assisted evidence analysis. We reviewed published material, not physical products.

Automated source and evidence checks completed on 2026-11-04. These checks are not veterinary review.

Research scope and outstanding checks

Searches covered Europe PMC-style queries for nutraceutical osteoarthritis systematic reviews in dogs, Flexadin Advanced with UC-II, and chicken cartilage for canine osteoarthritis. They are not exhaustive. Most trial sources were abstracts only, so methods, effect sizes and funding were often unavailable. Excluded from evidence rows: the 2022 meta-analysis (mixed dog and cat; dog-only results not separated in the text) and the scoping review (partly Vetoquinol-funded); both informed explanations. Also excluded: a NEXT-II collagen review (different ingredient, mostly mouse data), a 12-dog synovial-fluid study with no placebo group, older general systematic reviews with no UC-II results in their abstracts, and unrelated human and laboratory papers.

Focused research searches:

  • (TITLE_ABS:nutraceutical* AND TITLE_ABS:osteoarthrit* AND TITLE_ABS:systematic AND TITLE_ABS:review) AND (TITLE_ABS:dog OR TITLE_ABS:dogs OR TITLE_ABS:canine)
  • (TITLE_ABS:nutraceutical* AND TITLE_ABS:osteoarthrit* AND TITLE_ABS:systematic AND TITLE_ABS:review) AND (TITLE_ABS:dog OR TITLE_ABS:dogs OR TITLE_ABS:canine) sort_cited:y
  • (Flexadin AND Advanced AND UC-II) AND (TITLE_ABS:dog OR TITLE_ABS:dogs OR TITLE_ABS:canine)
  • (Flexadin AND Advanced AND UC-II) AND (TITLE_ABS:dog OR TITLE_ABS:dogs OR TITLE_ABS:canine) sort_cited:y
  • (TITLE_ABS:chicken AND TITLE_ABS:cartilage AND TITLE_ABS:osteoarthrit*) AND (TITLE_ABS:dog OR TITLE_ABS:dogs OR TITLE_ABS:canine)
  • (TITLE_ABS:chicken AND TITLE_ABS:cartilage AND TITLE_ABS:osteoarthrit*) AND (TITLE_ABS:dog OR TITLE_ABS:dogs OR TITLE_ABS:canine) sort_cited:y
  • A placebo-controlled trial of the Flexadin Advanced chew itself
  • Adequately sized head-to-head dog trial against glucosamine and chondroitin
  • Dog data on cartilage structure or repair
  • Product-specific independent testing of this chew against its label
  • Weight-based dosing information on the label

More dog supplements reviews

Check another product
Paste a product page to request an automated evidence review.